Molecular Glue Drugs: From Event-Driven Mechanisms to Chemically Induced Proximity Effects—A New Generation of Therapeutic Strategies

Author: Senior Product Manager of UA Views：13

This article systematically elucidates the "event-driven" pharmacological characteristics of molecular glue drugs, distinguishing them from traditional small molecules, by focusing on their mechanisms of action and therapeutic applications. It analyzes the molecular basis by which molecular glues induce the proximity of two proteins to form ternary complexes, thereby triggering target protein degradation, and explores the broad applications of chemically induced proximity effects in fields such as protein degradation, signal regulation, and gene editing.

Recent Advances
Product Information

Recent Advances

Molecular Glue Drugs: From Event-Driven Mechanisms to Chemically Induced Proximity Effects as a New Generation Therapeutic Strategy

Summary
This article systematically elucidates the "event-driven" pharmacological characteristics of molecular glue drugs, distinguishing them from traditional small-molecule drugs. It analyzes the molecular basis by which molecular glues induce the formation of ternary complexes between two proteins, leading to the degradation of target proteins, and explores the broad applications of chemically induced proximity effects in protein degradation, signal regulation, and gene editing.

I. Occupancy-Driven Pharmacological Effects of Traditional Small-Molecule Drugs

The pharmacological effects of traditional small-molecule drugs follow a one-drug-one-target paradigm, where even polypharmacology (including off-target effects) involves 1:1 binding interactions. Drug-target binding adheres to the law of mass action, with thermodynamic and kinetic properties determining the strength and duration of target inhibition or activation. The observed effects result from the drug occupying the active site of the target, termed occupancy-driven pharmacological action. This classical pharmacological paradigm has dominated drug discovery for decades, with its core logic relying on high-affinity binding of small molecules to the active sites of target proteins to block or modulate their function. However, occupancy-driven strategies have inherent limitations—approximately 85% of proteins lack suitable functional binding sites for small molecules, rendering most proteins inaccessible to traditional small-molecule drugs.

II. The Rise of Targeted Protein Degradation Technology and Event-Driven Mechanisms

Since the beginning of this century, targeted protein degradation technologies have emerged, epitomized by proteolysis-targeting chimeras (PROTACs), which have also revealed molecular glue drugs. Unlike traditional drug mechanisms, these drugs exhibit a one-drug-two-(or-more)-targets characteristic, where the drug molecule simultaneously or sequentially binds two distinct proteins to form a ternary complex, inducing interaction between the two proteins. One of these is the target protein, which undergoes structural degradation and functional loss.

The pharmacological effects resulting from such protein interactions are induced by PROTACs or molecular glues, though these molecules themselves do not participate in the degradation or inhibition process. Their role is to induce the event, hence termed event-driven pharmacological action. The core advantage of event-driven mechanisms lies in the fact that the drug molecule does not need to occupy the active site of the target protein for extended periods; it only needs to transiently induce the formation of the ternary complex to complete ubiquitination of the target protein. The drug molecule can then be recycled to participate in the next catalytic cycle. This catalytic property allows the drug to exert target protein degradation activity at low systemic exposure levels, potentially resulting in lower toxicity.

III. Chemically Induced Proximity Effects and Protein Interaction Mechanisms of Molecular Glues

Examining the essence of PROTAC and molecular glue mechanisms reveals that different structural elements of the molecule bind complementarily to two proteins, inducing and promoting their proximity to trigger effects. Thus, this can also be viewed as chemically induced proximity effects, potentially leading to chemically induced dimerization. Molecular glues and PROTACs differ significantly in molecular structure—molecular glues are typically monovalent small molecules with low molecular weight and lack explicit linker structures, whereas PROTACs are heterobifunctional molecules composed of a target protein ligand, an E3 ligase ligand, and a linker. Molecular glues function by inducing or enhancing interactions between two proteins, interactions that would not occur or would have very low affinity in the absence of the molecular glue.

The uniqueness of molecular glues lies in their mechanism, which relies more on the complementarity of protein-protein interaction interfaces. Molecular glue molecules typically bind to the surface of one protein, altering its conformation or surface properties to create a new interface with affinity for another protein. This mechanism enables molecular glues to target protein interfaces that are difficult to modulate with traditional small molecules, expanding the range of druggable targets.

IV. Broad Applications of Chemically Induced Proximity Effects

Chemically induced proximity effects involve bringing two proteins into proximity to interact and regulate cellular functions. These effects have been applied or observed in protein degradation, cellular signal regulation and cascades, gene expression and editing, and cell therapy, among other fields. In protein degradation, chemically induced proximity effects recruit E3 ligases to target proteins, enabling ubiquitination and degradation. In cellular signal regulation, these effects can induce receptor dimerization or oligomerization to activate or inhibit downstream signaling pathways. In gene expression and editing, they can bind specific endogenous transcription factors or epigenetic regulators to activate or suppress endogenous target genes, thereby inducing apoptosis in cancer cells, making them a breakthrough in targeted cancer therapy.

In cell therapy, chemically induced proximity effects can be used to regulate the activity of engineered T cells or NK cells, enabling precise control of cell functions dependent on small molecules. These applications demonstrate that chemically induced proximity effects have become a critical bridge connecting chemical biology and precision medicine.

V. Conclusion

In molecular glue drug research, GSPT1 is an important representative target. GSPT1 (G1 to S phase transition 1) is a translation termination factor that plays a key role in protein synthesis. Studies have shown that certain molecular glue compounds can induce the formation of a ternary complex between GSPT1 and the E3 ligase CRBN, leading to ubiquitination and degradation of GSPT1, thereby inhibiting protein synthesis in tumor cells and inducing apoptosis. GSPT1 has thus become a model target in molecular glue drug development, used to study molecular glue-induced protein degradation mechanisms and screen novel molecular glue compounds.

To meet the practical needs of molecular glue drug research, Uni offers GSPT1 GST tag Protein, Human. This product expresses GSPT1 protein fused with a GST tag, which facilitates high-purity purification via glutathione affinity chromatography and can be used for GST tag-based detection and capture. It is suitable for studying molecular glue-induced GSPT1 degradation mechanisms, analyzing GSPT1-CRBN ternary complex formation, and evaluating molecular glue compound activity in vitro, among other applications.

As a key branch of targeted protein degradation, molecular glue drugs offer novel strategic pathways for modulating traditionally undruggable targets through their unique event-driven pharmacological mechanisms and chemically induced proximity effects. The shift from occupancy-driven to event-driven pharmacology, from monovalent molecular glues to heterobifunctional PROTAC molecular designs, and from protein degradation to gene editing and cell therapy applications, molecular glue drugs continue to drive innovation in drug discovery. GSPT1 GST tag Protein, Human provides reliable tools for mechanistic analysis and activity evaluation in molecular glue drug research, supporting further exploration in this field.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next